2024-04-05 03:38:40
DAPA-HFㆍDELIVER meta-analysis…Overall, recently hospitalized patients are the most at risk
[의약뉴스] A study reported that the secondary event prevention effect of Farxiga (ingredient name: dapagliflozin) in heart failure patients was not affected by the time of hospitalization for heart failure.
The SGLT-2 inhibitor Farxiga is indicated for patients with heart failure with reduced ejection fraction (HFrEF) following DAPA-HF in patients with heart failure with preserved ejection fraction (HFpEF), heart failure with mild reduced ejection fraction (HFmrEF), and heart failure with improved ejection fraction (HFimpEF). The DELIVER study demonstrated the effectiveness of preventing secondary events (worsening heart failure or cardiovascular death) in a wide range of heart failure patients.
▲ A study reported that the effectiveness of Farxiga in preventing secondary events in heart failure patients was not affected by the time of hospitalization for heart failure.
Among these, on the 3rd, the American College of Cardiology journal JACC;Heart Failure published a patient-level report (Patient-Heart Failure) that evaluated the effectiveness of Farxiga in preventing secondary events by dividing patients who participated in the DAPA-HF and DELIVER studies according to the time when they were most recently hospitalized for heart failure. level) meta-analysis results were published.
A total of 12,007 people participated in the two studies, of which 12.4% had a history of hospitalization for heart failure within 3 months before randomization, 14.2% between 3 and 12 months, 16.8% had a history of heart failure more than 1 year ago, and 56.5% had a history of hospitalization for heart failure. had no history of hospitalization.
Among these, the risk of events related to the primary endpoint, such as heart failure worsening or cardiovascular death, was generally inversely proportional to the time of hospitalization for heart failure, and patients who were hospitalized more recently had a higher risk of events related to the primary endpoint.
Compared with placebo, the risk of events related to the primary endpoint was lower in the Forsyga group in all groups.
Among patients hospitalized within 3 months, 34% (HR=0.66, 95% CI 0.55-0.81), between 3 and 12 months, 27% (HR=0.73, 95% CI 0.59-0.90), and within 1 year, 9% ( HR=0.91, 95% CI 0.74, 1.12), and 18% (HR=0.83, 95% CI 0.73-0.94) in patients who were not hospitalized (Pinteraction=0.09).
At a median follow-up of 22 months, the number of patients needing treatment to reduce one event related to the primary endpoint was 13 for patients hospitalized within 3 months, 20 for 3 to 12 months, and 1 year or earlier. The number was 23 for patients who were not hospitalized, and 28 for patients who were not hospitalized.
Additionally, the benefits of Farxiga were consistent across all ranges of cardiac output, regardless of the time of heart failure hospitalization.
© Medicine News. Reproduction and redistribution prohibited.
1712293258
#Farxiga #consistent #benefits #heart #failure #hospitalization #period
